Plain-English translation of NCT03791034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying whether a blood test that detects tiny pieces of tumor DNA can help catch lung cancer recurrence earlier than traditional scans and imaging. When cancer cells die or break down, they release DNA into the bloodstream — this study will test whether measuring this cell-free tumor DNA can warn doctors about recurrence months before it shows up on a CT scan or X-ray.
Currently, doctors monitor lung cancer patients after surgery using regular imaging tests like CT scans, but these tests may not catch recurrence until the cancer has already started spreading. This research aims to find a faster, simpler blood test that could detect cancer coming back much earlier, when treatment is more likely to work.
You likely qualify if…
You likely don't qualify if…
As a participant, you would have blood samples drawn at various visits after your lung surgery to monitor for signs of cancer recurrence. Researchers will analyze your blood for tumor DNA and track your health outcomes over time, comparing how well this blood test detects recurrence compared to standard imaging scans. The study involves 700 participants total and is currently recruiting patients at Samsung Medical Center.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Korea
Samsung Medical Center
Collaborators
Guardant Health, Inc.
Enrollment target
~700 participants
Started
August 2017
Primary completion
December 2021
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in May 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jhingook Kim, MD
Samsung Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.